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Objective: The aim of this study was to determine by immunohistochemistry the presence and significance of p53 
and bcl-2 proteins in oral lichen planus (OLP) and oral squamous cell carcinoma (OSCC). 
Study Design: We used 21 cases diagnosed as OLP 16 diagnosed as OSCC and four normal gingival biopsies taken 
from healthy patients were used as controls. Slides were processed for immunohistochemistry using anti-p53 and 
anti-bcl-2 monoclonal antibodies. 
Results: We found p53 immunoexpression in 71.4� OLP cases and 6�.7� OSCC cases, with no immunoexpres-
sion in control cases.  Bcl-2 was negative for all OLP and OSCC cases, and mild positivity was observed in normal 
tissue. We found significant correlation among p53 expression and OSCC malignancy. 
Conclusions: Our results suggest that TP53 system mainly promotes a hyperproliferative state by cell cycle arrest 
of the OLP epithelial cells for repairing damaged DNA nor apoptosis and that anti-apoptotic action of bcl-2 is not 
important in this disease.
Key words: Oral lichen planus, oral squamous cell carcinoma, p53, Bcl-2, carcinogenesis, malignant transforma-
tion.
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Introduction
Lichen planus is a relatively common, chronic derma-
tologic disease affecting the oral mucosa. Most patients 
affected by lichen planus are adults and it has been re-
ported that malignant transformation of oral lichen pla-
nus (OLP) varies from 0� to 2.1� (1-4). More than 90� 
of the malignant neoplasms of the oral cavity are squa-
mous cell carcinomas of the lining mucosae and males 
are affected more often than females. In males, the 
country with the oral squamous cell carcinoma (OSCC) 
highest rate in the western world is currently France 
with elevated rates in some parts of Latin America (5).
Growth of keratinocytes is regulated by a delicate bal-
ance among molecules controlling cell survival such as 
bcl-2 and cell death as p53. bcl-2 is an anti-apoptotic 
membrane-associated molecule residing in the nuclear 
and mitochondrial membranes. It is inversely related to 
p53 since its expression prevents apoptotic cell death 
and its anti-apoptotic function is modulating the mito-
chondrial release of cytochrome c (6). 
Alternatively, the TP53 gene is a tumor suppressor gene 
that induces cell cycle arrest or apoptosis. p53 can ex-
ert its apoptotic functions inducing the expression of 
proteins involved in mitochondrial and death receptor-
induced apoptotic pathways. In this fashion, p53 induc-
es the expression of several mitochondrial proteins of 
the bcl-2 family and induces mitochondrial release of 
cytochrome c, which associates with Apaf-1 and cas-
pase 9 to form an apoptosome. Moreover, Bax protein 
heterodimerizes with bcl-2, abrogates its function and 
promotes apoptosis (6). 
The importance of both proteins in cell death and apop-
tosis in various oral diseases as OSCC, leukoplakia and 
other epithelial dysplasias and OLP has been the matter 
of intensive studies (6-9).
Many reports suggest that OLP is a potential pre-can-
cerous lesion and that both bcl-2 and p53 proteins can 
be involved in the malignant transformation of OLP to 
OSCC (2,4,10-20). Expression of both proteins in these 
lesions is not yet well established since conflicting re-
sults have been published (10-12, 21-25).
Therefore, the aim of this study was to determine by 
immunohistochemistry the presence of p53 and bcl-2 in 
OLP and OSCC and their possible involvement in the 
process of cancer development. 
Material and Methods
This study was made in the Department of Dermatol-
ogy of the Hospital General Manuel Gea González and 
in the Clinical and Experimental Pathology Labora-
tory of the División de Estudios de Posgrado e Investi-
gación. Facultad de Odontología, UNAM, both located 
in Mexico City. Specimens were biopsy tissues from 
37 patients with diagnosis of OLP and OSCC. A docu-
ment of informed consent was previously signed and a 
complete clinical history was made to all patients. The 
protocol of this study was previously approved by the 
Ethics Committees of both institutions; five specimens 
from normal gingiva of clinically healthy subjects were 
also collected. OLP cases were graded as the WHO 
guidelines (26) in: reticular (r-OLP), erosive (e-OLP) 
and cases with reticular and erosive areas were classi-
fied as OLP mixed type (m-OLP). For OLP diagnosis, 
the clinico-pathological rules suggested by Al-Hashimi 
et al. (27) were used. 
All specimens were fixed in 10% buffered formalin for 
24 hours and routinely processed to obtain 5µ thick sec-
tions. H&E staining was used to confirm the original 
diagnosis, and to classify OSCC in low, intermediate 
and high grade. 
Immunohistochemistry. Six deparafinized sections 
each case (three for each monoclonal antibody) were 
soaked in 10 mM/L, pH 6, citrate buffer and placed in 
a microwave oven during 10 min for antigen retrieval. 
Endogenous peroxidase was blocked using 0.3� H2O2 
solution in methanol for five minutes at room tempera-
ture. Then, sections were rinsed in PBS for five minutes 
and covered with horse normal serum for 20 minutes at 
room temperature. Sections were incubated for 40 min-
utes at room temperature with monoclonal antibodies 
against p53 (NCI-953DO-7) and bcl-2 proteins (mouse 
clone 124), both antibodies were purchased from Dako 
(Carpinteria, CA). After washing in PBS, 2-3 drops of 
secondary antibody (Elite, PK-6102) were added and the 
sections were incubated for 20 minutes at room temper-
ature. After two PBS rinses, all sections were counter-
stained with Mayer’s haematoxylin and mounted. Addi-
tional sections running in parallel but with omission of 
the primary antibodies, served as negative controls. 
Specimens were examined microscopically to score p53 
and bcl-2 staining intensity. Less than 5� of stained 
cells was graded negative (-); 6-25� positive cells was 
recorded as mild (+); 26-50� positive cells was scored 
as moderate (++) and more than 50� as intense (+++). 
Counting was made in not less than 100 cells per slide 
and a mean of positive cells obtained from all three ana-
lyzed slides per case was obtained. This analysis was 
performed by two well trained, previously calibrated 
Oral Pathologists (k=0.05). Student’s T test and Pear-
son’s correlation coefficient analysis were performed, 
p<0.05 was considered statistically significant. 
Results
Clinical findings. Twenty-one out of 37 patients were 
diagnosed with OLP. Patients’ age varied from 22 to 74 
years (56+12.3 years). 76.2� were females, and tobacco 
and alcohol users corresponded to 2�.6� and 14.3� re-
spectively. In 14 cases (66.7�) OLP lesions involved oral 
tissues only; oral cavity and skin were 5 cases (23.��); 
and oral cavity and genitals were 2 cases (9.5�). OLP 
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lesions were located in buccal mucosa (n= 11; 52.4�), lips 
(n= �; 3�.1�), dorsal tongue and hard palate (n= 1; 6.3� 
respectively). Ten cases were classified as e-OLP, seven 
as m-OLP and four as r-OLP. 16 patients had OSCC; age 
range was from 33 to 93 years (66.�+14.4 years). 75� were 
male, 62.5� were tobacco users and 43.�� drank alcohol. 
OSCC cases were located as follows: labial mucosa (eight 
cases; 50�), lateral borders of the tongue (four cases; 25�), 
buccal mucosa (two cases; 12.5�), gingiva (one case; 
6.3�), and another case involved the gingiva and buccal 
mucosa (6.3%). Microscopically, 10 cases were classified 
as low grade, 5 as intermediate and one as high grade. 
p53 Immunoexpression. Immunoreactivity was observed 
as a brownish staining in the cellular nucleus (Fig. 1), it 
was negative in the normal tissues and six OLP cases, mild 
in 10, moderate in three and intense in two cases. Both cas-
es with intense p53 expression were e-OLP type. (Table 1) 
shows p53 immunoexpression according to OLP type. No 
statistical significance was found among p53 expression 
and gender, age, alcohol or smoking habits, and location 
of the lesions (p>0.05). Statistical significance was found 
only among p53 expression and clinical types of OLP (p< 
0.02). 
p53 expression was negative in 5 OSCC cases (31.2�); 
mild in 4 (25�) and intense in 7 cases (43.��). (Table 1) 
shows p53 immunoexpression according to OSCC ma-
lignancy. Mild expression predominated in cases of low 
grade malignancy; and the only case classified as high 
grade showed intense expression of p53 (Fig. 2). Normal 
tissue did not show p53 expression. We found statistically 
significant correlation among p53 expression and the de-
gree of malignancy of the studied cases (p<0.03). When 
we analyzed the correlation among gender, age, smoking 
habit, alcoholism and location of the OSCC cases with 
p53 immunoexpression, no statistically significant differ-
ences were found (p>0.05). There was statistical differ-
ence among p53 immunoexpression in OSCC and OLP 
cases. (p<0.001).
Bcl-2 immunoexpression. It was negative in all OLP and 
OSSC cases. In normal tissue a mild positivity was seen 
in the cytoplasm of the basal cells (Fig. 3). 
Fig. 1. Photomicrograph showing intense p53 immunopositivity in 
lichen planus. p53 immunostaining technique. 400X.
p53 EXPRESSION 
- + ++ +++ TOTAL 
TYPE OF OLP 
EROSIVE 3 3 2 2 10 
MIXED 2 4 1 --- 7 
RETICULAR 1 3 --- --- 4 
TOTAL 6 10 3 2 21 
OSCC MALIGNANCY 
LOW 3 4 --- 3 10 
INTERMEDIATE 2 --- --- 3 5 
HIGH --- --- --- 1 1 
TOTAL 5 4 0 7 16 
Table 1. p53 Immunoexpression In Studied  Cases.
- = negative; += mildly positive: ++= moderately positive  +++= 
intensely positive.
Fig. 2. Intense p53 immunoexpression in an oral squamous cell car-
cinoma. p53 immunostaining technique. 400 X.
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Discussion
Despite there are not factors clearly associated with ma-
lignant transformation to oral lichen planus. OLP has 
been regarded as a premalignant condition; this prema-
lignant potential has been demonstrated by the results 
in previously published studies (2-4). This implies that 
a patient with OLP has an increased risk for developing 
OSCC, but not necessarily in an existing OLP lesion. 
p53 and bcl-2 have been related to malignant transfor-
mation of oral epithelial cells (6-9, 23,25). It has been 
considered that the long term permanence of OLP in the 
oral cavity is probably the factor that triggers its malig-
nant transformation and it is specially risky with e-OLP 
and if it stays for more than five years (2-4 ,27). 
p53 immunoexpression was reported in OLP (10-12, 
14,15,19,21,23) and in our study, 71.5� of OLP cases 
were positive. Out of these cases, 7 were of e-OLP and 
two of them showed intense positivity. p53 expression 
in OSCC has been reported in up to �1� of the cases 
(7,21,23). In this study, 6�.�� of our OSCC cases were 
p53 positive; and this figure is consistent with the above 
mentioned studies. Our results and those previously re-
ported (7-9) indicate that p53 expression is related with 
the malignant degree of OSCC. In contrast, other re-
ports found no correlation (12,13,2�).
We failed to demonstrate the value of p53 as a predic-
tor for OLP transformation to OSCC since 15/21 OLP 
studied cases showed p53 positivity. These results sug-
gest that may be p53 is an inaccurate tool for predict-
ing OLP malignant transformation. This suggestion 
is supported because the majority of the OLP studied 
cases were positive to p53 and this prediction value is 
challenged because it is reasonable to assume that the 
majority of these p53-positive cases will never trans-
form to OSCC. In our study, we found that p53 expres-
sion rate in OSCC and OLP were similar (6�.�� and 
71.5� respectively), these results may suggest there are 
another cellular mechanisms involved in transformation 
of OLP to OSCC. 
There has been proposed a hypothesis that malignant 
transformation is a consequence of alterations in cell 
cycle control affecting extensive areas of the oral mu-
cosa (14). Previous results (10,14,15,29,30), indicate that 
apoptosis is of scant importance in the disease, and that 
many damaged basal epithelial cells respond to aggres-
sion by increasing their proliferation rate (15-17). Re-
cent findings suggest that this hyperproliferative state 
constitutes a form of cell response attempting to pre-
serve the epithelial structure avoiding the appearance 
of ulcerations (15,1�). However, the malignant trans-
formation rate of OLP is low and as it was previously 
suggested, this low rate of malignant transformation in 
OLP is due to activation of the TP53 system, which ex-
erts priority action to promote the repair of damaged 
DNA (15,1�). In this context, the cases of malignization 
could correspond to situations where mutations or other 
inactivating mechanisms prevent the TP53 system from 
acting correctly and this in turn possibly constitutes a 
key element for initiation of the malignant transforma-
tion process. 
A number of authors estimate that TP53 overexpression 
constitutes a form of cell response to the hyperprolifer-
ative state frequently seen in OLP (17,19,20). González-
Moles et al. results (18) suggested a significant associa-
tion among p53 and Ki-67 expression, and they did not 
accept that the epithelium associates cell proliferation 
(Ki-67 positive cells) and cell cycle arrest/apoptosis 
(p53-positive cells). 
González-Moles et al. (1�) concluded that in OLP, the 
TP53 system is frequently activated fundamentally to 
arrest the cell cycle and to improve DNA repair, since 
they observed no association among p53 and caspase-3 
expression. As it was previously reported (15,1�,30), 
this form of response to aggression with low apopto-
sis, frequent wild p53 expression and increased cell 
proliferation rate constitutes a molecular mechanism 
designed to preserve the epithelium in OLP to avoid ul-
cerations. Recent observations reinforce this hypothesis 
because the lack of association found among p53 and 
Ki-67 expression (1�). These results suggest that the hy-
perproliferative state of OLP is not secondary to TP53 
mutation. 
It is possible that p53 mutations may constitute an im-
portant oncogenic event in malignantly transformed 
Fig. 3. Normal tissue showing mild immunoexpression to bcl-2. 400 
X.
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OLP, with generation of a new cell population with 
summative oncogenic events which led to acquisition 
of a malignant phenotype. Thus, the low frequency of 
p53 mutations could explain the low malignization rate 
of OLP (1�). It is possible that p53 over expression in the 
erosive type of OLP can not be related to its possible 
malignant transformation to OSCC, since only 23.�� of 
the OLP cases analyzed in this study showed moderate 
to intense immunoexpression to this protein. 
Previously reported findings regarding bcl-2 expression 
in OSSC are controversial (10-13, 23-25, 27). Jordan 
et al (27) reported cytoplasmic expression in 60� of 
their studied OSCCs suggesting that bcl-2 expression 
in poorly differentiated OSCC cases was due to malig-
nant keratinocyte inability to reach final differentiation, 
maintaining a bcl-2 phenotype of the mother cell. Two 
reports (22,2�) demonstrated an inverse correlation 
among p53 and bcl-2 expression in OSCC suggesting 
that one of these proteins could substitute the other dur-
ing carcinogenesis and that TP53 gene can downregu-
late the bcl-2 gene during the apoptotic process. Our 
results support this point of view since all our OSCC 
cases were negative for bcl-2 protein.
As it was in other studies (11,22,2�), our results show 
that there were no bcl-2 expression in the OLP studied 
cases. Results from these studies suggest that bcl-2 pro-
tein does not seem to be involved in the OLP epithelial 
changes, since no immunoreactivity was seen; these re-
sults also suggest that loss of the bcl-2 anti-apoptotic 
control is associated with a concomitant loss of other 
pro-survival molecules or an increase in the pro-apop-
totic molecules in OLP. It is also possible that a combi-
nation of long term survival of the bcl-2 negative OLP 
cells and strong p53 immunoexpression could account 
to increase the potential to malignant transformation in 
e-OLP cases. In contrast Tanda et al. suggested that the 
absence of low rate of apoptosis in OLP is a consequence 
of the anti-apoptotic action exerted by bcl-2 (11).
Data concerning bcl-2 expression in OSCC is not uni-
form, with positivity varying from 23 to 100� (�,9,22). 
It is interesting to note, that contrasting to several stud-
ies, all our OSCC cases were negative for bcl-2. This 
disparity in bcl-2 expression from different studies may 
reflect subtle inherent differences in upstream genetic 
events among different populations, gender and age of 
the patients, anatomical location of the studied lesions 
and possibly differences in the environmental, hygienic 
and dietary conditions. 
It is possible that alterations in mutation of the TP53 
and bcl-2 systems may play an important role in the 
development of OSCC probably by allowing the neo-
plastic cells to escape from apoptosis. In summary, both 
lichen planus and OSCC show similar expressions for 
p-53 and bcl-2, and it is possible that alterations of these 
genes may be relevant in the long term transformation 
process of OLP to OSCC. There are other mechanisms 
potentially involved in the OLP change to OSCC. If the 
apoptotic phenomenon is of little importance in OLP 
(14,15), this is a surprising conclusion in an epithelium 
subjected to an intense and persistent autoimmune ag-
gression. They propose that OLP cells respond more 
frequently with arrest or senesce than with apoptosis. 
It is also possible that the action by different oncogenic 
insults on proliferating OLP cells may play a role in the 
transformation of OLP to OSCC (1-4,14).
The results of our study and those from others (14,15) 
agree in that it may be a consequence of alterations in 
the cycle cell control mechanisms affecting wide areas 
of the oral mucosa and that the low rate of apoptosis 
and the increased rate of the OLP affected epithelium 
will serve to maintain the epithelial architecture that 
may underline a predisposition to developing cancer in 
OLP affected tissues and that malignant transformation 
would presumably be favored by a failure of the TP53 
system permitting that proliferating cells do not enter to 
apoptosis and that they are under the TP53 system and 
that these events could led to accumulation of a malig-
nant cell phenotype.
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